On January 31, 2018, BCC Research analyst Smruti Munshi presented a Member-exclusive webinar on the future of mobile apps for DNA sequencing, and more specifically, smartphone apps used to interpret the data for both genealogical and medical applications. The technology is in a nascent stage, and the possibilities are seemingly endless. Senior Editor Chris Spivey captures the frontier-nature of DNA sequencing in his introduction, which is transcribed below.
The development of novel enzyme inhibitors has led to effective therapeutic options for diseases that were once considered difficult to treat. A newly updated study by BCC Research finds that approvals of new molecular entities will drive the global market for enzyme inhibitors to $179.9 billion by 2022. Enzyme inhibitors offer therapeutic options for myriad illnesses, including HCV, HIV, cancer, gastrointestinal disease, cardiovascular disease, inflammatory disorders, rheumatoid arthritis, neurological disorders (depression, Parkinson’s disease, Alzheimer’s disease) and diabetes.
There has been increasing interest in botanical drugs, with many players investigating their commercial potential. According to BCC Research, the global market for plant-derived and botanical drugs is expected to reach $39.6 billion by 2022. Excluding botanicals, growth in the plant-derived drug market is in line with the overall pharmaceutical industry, given the presence of generics (including biosimilars). Patent expirations will necessitate medicinal compounds other than single chemical entities. Growth in the U.S. market for plant-derived drugs will reflect new cannabinoids and their overall expanded uses, as well as eventual brand line extensions.